Evidence map›Paper›PMID 40574966›Full record

ArticleTherapeutic advances in medical oncology2025

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update.

Jessica S W Borgers, Theresa M Medina, William A Robinson, Kasey L Couts, Elizabeth N Katsnelson, Claire M Muckle, Eduardo Davilla, Sapna P Patel, Dexiang Gao, Richard P Tobin and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03200847 (Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03200847 phase1 / phase2completednot on this map

Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma

TypeinterventionalSponsorUniversity of Colorado, DenverRan2017 to 2022Enrolled26ConditionsStage IV Melanoma, Stage III Melanoma, Advanced MelanomaArmsPembrolizumab with All-Trans Retinoic Acid
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jessica S W BorgersDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID https://orcid.org/0000-0002-6478-7821
Theresa M MedinaDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
William A RobinsonDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Kasey L CoutsDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Elizabeth N KatsnelsonDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Claire M MuckleDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Eduardo DavillaDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Sapna P PatelDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Dexiang GaoDepartment of Pediatrics, School of Medicine, University of Colorado Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Richard P TobinDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID https://orcid.org/0000-0003-3890-4534
Martin D McCarterDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, 12631 East 17th Avenue, C325, Aurora, CO 80045, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary analysis of the phase I/II clinical trial combining pembrolizumab with all-trans retinoic acid (ATRA) for patients with metastatic melanoma showed a median progression-free survival (PFS) of 20.3 months and median overall survival (OS) not reached. Objective: Report 5-year OS and PFS rates. Design: In this single-center, single-arm trial (NCT03200847), 24 anti-PD-1 naïve patients with metastatic melanoma were enrolled between 10/2017 and 07/2020. Methods: The Kaplan-Meier method was used to estimate OS and PFS. Results: At data cutoff (May 14, 2024), all patients had completed treatment, and 58% ( Conclusion: These results underscore the long-term clinical benefit of combining anti-PD-1 with ATRA, with survival rates comparable to anti-PD-1/combinations but with lower toxicity.

Indexed as

anti-PD-1ATRAclinical trialimmune-checkpoint blockademelanoma

Identifiers

PMID40574966
PMCPMC12198584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.